We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Association Between Obstructive Sleep Apnea and Metabolic Abnormalities in Patients With Hypertrophic Cardiomyopathy.
- Authors
Juan Wang; Haobo Xu; Jiansong Yuan; Chao Guo; Fenghuan Hu; Weixian Yang; Lei Song; Xiaoliang Luo; Rong Liu; Jingang Cui; Shengwen Liu; Yushi Chun; Shubin Qiao; Wang, Juan; Xu, Haobo; Yuan, Jiansong; Guo, Chao; Hu, Fenghuan; Yang, Weixian; Song, Lei
- Abstract
<bold>Objectives: </bold>Metabolic abnormalities have been associated with long-term cardiac mortality in patients with hypertrophic cardiomyopathy (HCM). Obstructive sleep apnea (OSA) is a risk factor for metabolic abnormalities in general populations, but association between OSA and metabolic abnormalities in HCM is still undefined. This study aimed to investigate the relationship between OSA and metabolic dysfunction in a large series of patients with HCM.<bold>Methods: </bold>A total of 587 patients with HCM who underwent sleep evaluations at Fuwai Hospital were included. Data from clinical characteristics, polysomnography studies, and metabolic measurements were collected.<bold>Results: </bold>OSA was present in 344 patients (58.6%). Patients with OSA were older, more often male, and had more clinical comorbidities. Body mass index, blood pressure, fasting glucose, and triglycerides all increased (all P < 0.001) and high-density lipoprotein cholesterol decreased (P = 0.046) with the severity of OSA. In multivariate analysis, moderate to severe OSA and Log (apnea-hypopnea index + 1) were independently associated with obesity (odds ratio [OR], 2.42; 95% CI, 1.48-3.95 and OR, 1.60; 95% CI, 1.31-1.95), elevated blood pressure (OR, 1.99; 95% CI, 1.42-3.26 and OR, 1.31; 95% CI, 1.08-1.60), and elevated triglycerides (OR, 1.71; 95% CI, 1.05-2.78 and OR, 1.24; 95% CI, 1.02-1.51 but not elevated fasting glucose (OR, 0.88; 95% CI, 0.50-1.52 and OR, 1.02; 95% CI, 0.82-1.28) or reduced high-density lipoprotein cholesterol (OR, 1.30; 95% CI, 0.83-2.04 and OR, 1.06; 95% CI, 0.89-1.27).<bold>Conclusions: </bold>Severity of OSA is independently associated with some profiles of metabolic abnormalities. Clinical trials are required to determine whether OSA treatment improves metabolic abnormalities and long-term outcomes in patients with HCM.
- Subjects
ICELAND; SLEEP apnea syndromes; HYPERTROPHIC cardiomyopathy; SYSTOLIC blood pressure; BLOOD lipids; HDL cholesterol; LDL cholesterol; CARDIOVASCULAR diseases; RESEARCH; CARDIAC hypertrophy; RESEARCH methodology; POLYSOMNOGRAPHY; MEDICAL cooperation; EVALUATION research; METABOLIC disorders; SLEEP; SEVERITY of illness index; COMPARATIVE studies; DISEASE prevalence; COMORBIDITY; DISEASE complications
- Publication
Journal of Clinical Endocrinology & Metabolism, 2021, Vol 106, Issue 5, pe2309
- ISSN
0021-972X
- Publication type
journal article
- DOI
10.1210/clinem/dgab015